{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-162715","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.158323+00:00","generated_at":"2026-06-01T04:06:53.476754+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Summit Therapeutics director Ujwala Mahatme resigns; annual meeting elects all eight nominees","bullets":["Director Ujwala Mahatme resigned effective June 12, 2024, to focus on professional commitments; no disagreement with company.","At June 14 annual meeting, all eight director nominees elected with large majorities (e.g., Robert W. Duggan received 620.6M votes).","Stockholders ratified PwC as independent auditor for FY 2024 with 639.3M votes for and 39.8K against.","Non-binding advisory vote on executive compensation passed with 604.2M for, 15.9M against, and 18.9M broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-162715","json":"https://secwatch.observer/filing/0001193125-24-162715.json","markdown":"https://secwatch.observer/filing/0001193125-24-162715.md","text":"https://secwatch.observer/filing/0001193125-24-162715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000119312524162715/0001193125-24-162715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000119312524162715/d786440d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:06:53.476754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cc5487dc0","claim":"Ujwala Mahatme resigned as Director at Summit Therapeutics Inc..","evidence_excerpt":"Effective June 12, 2024, Ujwala Mahatme informed Summit Therapeutics Inc. (the “Company”) that she was resigning from her role as a member of the Board of Directors (the “Board”) of the Company, and from each committee of the Board, to focus on her increasing professional commitments outside the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000119312524162715/0001193125-24-162715-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}